With the rapid development of new, highly efficient anticancer drugs such as checkpoint inhibitors, an expanded spectrum of side effects of oncological therapies inevitably arises. The increasing use of immunotherapy requires knowledge of these potential adverse effects and also strategies for their management. While the overall picture of the range, extent, and frequency of side effects is slowly coming together with wider use outside of trials, methods for their prophylaxis and therapy are being diligently tested.